阅读说明：本技术 一种甘草酸二铵的应用 (Application of diammonium glycyrrhizinate ) 是由 韩乾国 于 2021-10-29 设计创作，主要内容包括：本发明属于药物技术领域,具体涉及一种甘草酸二铵的应用。采用甘草酸二铵作为治疗慢性低血压的药物。本发明采用甘草酸二铵治疗慢性低血压,可有效提高患者血压,并且无皮质激素的不良反应,长期服用耐受性良好,反馈性抑制肾上腺功能作用较小,故作用稳定。(The invention belongs to the technical field of medicines, and particularly relates to application of diammonium glycyrrhizinate. Diammonium glycyrrhizinate is adopted as a medicine for treating chronic hypotension. The diammonium glycyrrhizinate is adopted to treat chronic hypotension, the blood pressure of a patient can be effectively improved, adverse reactions of cortical hormone are avoided, the tolerance is good after long-term administration, and the feedback inhibition effect on adrenal gland function is small, so that the effect is stable.)

1. The application of diammonium glycyrrhizinate is characterized in that diammonium glycyrrhizinate is used as a medicine for treating chronic hypotension.

Technical Field

The invention belongs to the technical field of medicines, and particularly relates to application of diammonium glycyrrhizinate.

Background

Generally, adult systolic blood pressure is lower than 90mmHg and diastolic blood pressure is lower than 60mmHg, which is called hypotension. Hypotension can be classified as acute hypotension, chronic hypotension and orthostatic hypotension. Chronic hypotension belongs to physiology, is related to personal physique, family inheritance and the like, if induction factors are met, the blood pressure is rapidly reduced, vasomotor dysfunction is induced to generate syncope, the syncope is often seen in young and weak women, obvious inducement (such as fatigue, emotional stress, fear and the like) is frequently caused in the attack, and the chronic hypotension is more likely to occur under the conditions of hot weather, foul air, fatigue, insomnia and the like. In the process of syncope, there may be upper abdominal discomfort, nausea, pale complexion, limp limbs, even transient loss of consciousness, often accompanied by significant blood pressure drop, cold and damp hands and feet, weak and thready pulse, and decreased urine volume, and the occurrence mechanism is transient vascular bed dilatation caused by various stimulation vagus nerve reflexes. In the chronic state, women with the onset age of 18-35 years are more in the city than in the countryside, and the onset causes are closely related to family genetic factors. The clinical symptoms are mostly absent when the blood pressure is 90/60mmHg, dizziness, fatigue and other clinical manifestations are mostly present when the blood pressure is continuously lower than 90/50mmHg or the blood pressure is suddenly reduced, and the cause is difficult to judge because the symptoms are quickly and naturally recovered after the onset, so the clinical symptoms obviously become the focus of attention of people unlike hypertension due to high morbidity and great harm, and at present, a specific treatment scheme for the hypotension is not available, and even the hypotension is ignored by people. When hypotension patients often have dizziness, hypodynamia and syncope, life and work are affected, and anxiety and uneasiness are caused to the patients. At present, western medicine treatment generally adopts nutrition-added diet, attention is paid to rest, energy is supplemented, even individual men drink high-alcohol liquor for a long time as a test treatment means, the effect is very little, the symptoms are treated, the root causes are not treated, and the effect is not ideal.

Disclosure of Invention

The invention discloses application of diammonium glycyrrhizinate, and aims to solve the problems that the existing hypotension treatment mode in the background technology has a very small effect, treats both symptoms and root causes, and has an undesirable effect.

In order to solve the technical problems, the technical scheme adopted by the invention is as follows:

the application of diammonium glycyrrhizinate as medicine for treating chronic hypotension is disclosed.

The effect of the invention is further illustrated by the treatment data below:

the patients: wu Chi; age: 48; the systolic pressure before treatment was: 86.4 of the total weight of the mixture; the diastolic pressure is: 54.5 of the total weight of the mixture;

after oral administration of diammonium glycyrrhizinate: after taking for one week, the systolic blood pressure is 99.7; the diastolic pressure is: 58.9 of the total weight of the mixture;

after one month of administration: systolic pressure of 120.8; the diastolic pressure is: 65.2;

after three months of administration: systolic blood pressure 118.6; the diastolic pressure is: 63.4;

from the above, the present invention has achieved a better clinical effect in treating hypotension.

In summary, due to the adoption of the technical scheme, the invention has the beneficial effects that: the invention adopts diammonium glycyrrhizinate as an oral pressure-increasing medicine, has obvious treatment effect on chronic hypotension, can effectively improve the blood pressure of patients, has no adverse reaction of cortical hormone, has good tolerance after long-term administration, has less feedback inhibition effect on adrenal gland function, and has stable effect.

Detailed Description

The technical solutions in the embodiments of the present application are clearly and completely described below, and it is obvious that the described embodiments are only a part of the embodiments of the present application, and not all embodiments. Thus, the following detailed description of the embodiments of the present application is not intended to limit the scope of the claimed application, but is merely representative of selected embodiments of the application. All other embodiments, which can be derived by a person skilled in the art from the embodiments of the present application without making any creative effort, shall fall within the protection scope of the present application.

The application of diammonium glycyrrhizinate as medicine for treating chronic hypotension is disclosed.

The effect of the invention is further illustrated by the treatment data below:

the patients: wu Chi; age: 48; the systolic pressure before treatment was: 86.4 of the total weight of the mixture; the diastolic pressure is: 54.5 of the total weight of the mixture;

after oral administration of diammonium glycyrrhizinate: after taking for one week, the systolic blood pressure is 99.7; the diastolic pressure is: 58.9 of the total weight of the mixture;

after one month of administration: systolic pressure of 120.8; the diastolic pressure is: 65.2;

after three months of administration: systolic blood pressure 118.6; the diastolic pressure is: 63.4;

the invention adopts diammonium glycyrrhizinate as an oral pressure-increasing medicine, has obvious treatment effect on chronic hypotension, can effectively improve the blood pressure of patients, has no adverse reaction of cortical hormone, has good tolerance after long-term administration, has less feedback inhibition effect on adrenal gland function, and has stable effect.

The above-mentioned embodiments only express the specific embodiments of the present application, and the description thereof is more specific and detailed, but not construed as limiting the scope of the present application. It should be noted that, for those skilled in the art, without departing from the technical idea of the present application, several changes and modifications can be made, which are all within the protection scope of the present application.